作者：
Yawara,Kawano [1]
;
Kihyun,Kim [2]
;
Chang Ki,Min [3]
;
Youngil,Koh [4]
;
Kenichi,Ishizawa [5]
;
Sung Hyun,Kim [6]
;
Shigeki,Ito [7]
;
Junji,Tanaka [8]
;
Michihiro,Uchiyama [9]
;
Tadao,Ishida [10]
;
Jin Seok,Kim [11]
;
Philippe,Moreau [12]
;
Thomas,Martin [13]
;
Keisuke,Tada [14]
;
Marie-Laure,Risse [15]
;
Kenshi,Suzuki [16]
作者单位：
Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan. Electronic address: yawara.kawano@gmail.com.
[1]
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
[2]
Department of Hematology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
[3]
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
[4]
Department of Hematology and Cell Therapy, Yamagata University, Yamagata, Japan.
[5]
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea.
[6]
Division of Hematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan.
[7]
Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
[8]
Department of Hematology, Japanese Red Cross Society, Suwa Hospital, Suwa, Japan.
[9]
Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
[10]
Department of Hematology, Severance Hospital, Seoul, Republic of Korea.
[11]
Department of Hematology, University Hospital of Nantes, Nantes, France.
[12]
Department of Medicine, University of California, San Francisco, CA.
[13]
Research and Development, Sanofi K.K., Tokyo, Japan.
[14]
Sanofi Research and Development, Vitry-sur-Seine, France.
[15]
Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan.
[16]
DOI
10.1016/j.clml.2023.06.011
PMID
37479547
发布时间
2023-11-02
换一批
换一批
